{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037167","form_type":"8-K","ticker":"AHCO","cik":"0001725255","company_name":"AdaptHealth Corp.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.197262+00:00","generated_at":"2026-06-08T16:28:11.590081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AdaptHealth Q3 revenue up 6.3% to $804M; net loss $454M on $512M goodwill impairment; cuts FY EBITDA guidance","bullets":["Net revenue $804.0M (+6.3% YoY); net loss $454.1M vs prior year income $16.1M due to $511.9M goodwill impairment.","Adjusted EBITDA $161.2M (+0.6% YoY); YTD cash from ops $325.4M, free cash flow $76.6M.","FY23 guidance: revenue narrowed to $3.160–3.185B; EBITDA lowered to $630–650M (from $650–680M). Capex 10–12%; FCF 3–4% unchanged.","Subsequent to quarter-end, repurchased $19.4M of common stock under share repurchase authorization.","Management cites sleep product growth for record revenue; Humana contract delays weighed on EBITDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037167","json":"https://secwatch.observer/filing/0001628280-23-037167.json","markdown":"https://secwatch.observer/filing/0001628280-23-037167.md","text":"https://secwatch.observer/filing/0001628280-23-037167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725255/000162828023037167/0001628280-23-037167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725255/000162828023037167/ahco-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:28:11.590081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5139929a69f2a8d263fb2b917906db22e94b94a6","claim":"AdaptHealth Corp. reported third quarter ended September 30, 2023 results: revenue $804.0 million, net income Net loss attributable to AdaptHealth Corp. was $454.1 million. Guidance lowered.","evidence_excerpt":"quarter ended September 30, 2023. Third Quarter Results and Highlights All comparisons are to the quarter ended September 30, 2022 unless otherwise stated. • Net revenue was $804.0 million compared to $756.5 million, an increase of 6.3%. • Net loss attributable to AdaptHealth Corp. was $454.1 million compared to net income of $16.1 million, largely resulting from a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725255/000162828023037167/0001628280-23-037167-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$804.0 million"},{"label":"Net income","value":"Net loss attributable to AdaptHealth Corp. was $454.1 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}